Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 12/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188457 | 1.00 | PRCP (0.44) | PRCPCYP2D6CXCR4CYP3A4CHRM3 | |
| SCHEMBL20482729 | 0.94 | PRCP (0.44) | PRCPCYP2D6CXCR4 | |
| SCHEMBL4170855 | 0.94 | PRCP (0.44) | PRCPCYP2D6CXCR4 | |
| SCHEMBL4181457 | 0.94 | PRCP (0.44) | PRCPCYP2D6CXCR4 | |
| SCHEMBL4173733 | 0.94 | PRCP (0.44) | PRCPCYP2D6CXCR4 | |
| SCHEMBL4170860 | 0.94 | PRCP (0.44) | PRCPCYP2D6CXCR4 | |
| SCHEMBL13875186 | 0.94 | PRCP (0.44) | PRCPCYP2D6CXCR4 | |
| SCHEMBL4173013 | 0.84 | CHRNB2 (0.43) | PRCPCYP2D6CXCR4 | |
| SCHEMBL5547748 | 0.78 | CXCR4 (0.42) | CYP2D6CXCR4CYP3A4OPRM1 | |
| SCHEMBL1698216 | 0.74 | HDAC1 (0.40) | CYP2D6CXCR4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093454-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20090093454-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20090093454-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093454-A1 | Chemical Compounds | SLC10A1, CYP11B2, CYP4F3 | PRCP 679/4885CYP2D6 13/4885CXCR4 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.